Suppr超能文献

用于痴呆症的淀粉样蛋白PET配体

Amyloid PET Ligands for Dementia.

作者信息

Villemagne Victor L, Rowe Christopher C

机构信息

Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia; The Mental Health Research Institute of Victoria, 135 Oak Street, Parkville, Victoria 3052, Australia; Department of Medicine, Austin Health, Victoria 3084, Australia.

Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia; Department of Medicine, Austin Health, Victoria 3084, Australia.

出版信息

PET Clin. 2010 Jan;5(1):33-53. doi: 10.1016/j.cpet.2009.12.008. Epub 2010 May 27.

Abstract

The progressive nature of neurodegeneration suggests an age-dependent process that ultimately leads to synaptic failure and neuronal damage in cortical areas of the brain critical for memory and higher mental functions. The increasing age of the population in developed countries suggests that, if unchecked, these disorders will become increasingly prevalent. In the absence of specific biologic markers, direct pathologic examination of brain tissue still is the only definitive method for establishing a diagnosis of Alzheimer disease (AD) and other types of dementia. Pathologic hallmarks of AD are intracellular neurofibrillary tangles (NFT) and extracellular amyloid plaques. NFT are intraneuronal bundles of paired helical filaments mainly composed of the aggregates of an abnormally phosphorylated form of tau protein; neuritic plaques consist of dense extracellular aggregates of β-amyloid (Aβ), surrounded by reactive gliosis and dystrophic neurites. To date, all available evidence strongly supports the notion that an imbalance between the production and removal of Aβ leading to its progressive accumulation is central to the pathogenesis of AD. A growing understanding of the molecular mechanisms of Aβ formation, degradation, and neurotoxicity is being translated into new therapeutic approaches. Whereas AD is the most common cause of dementia in the elderly, postmortem studies have found dementia with Lewy Bodies and frontotemporal lobe degeneration each to account for about 20% of cases. Molecular neuroimaging techniques such as PET have been used for the in vivo assessment of molecular processes at their sites of action, permitting detection of subtle pathophysiological changes in the brain at asymptomatic stages The development of molecular imaging methods for noninvasively assessing disease-specific traits such as Aβ burden in AD is allowing early diagnosis at presymptomatic stages, more accurate differential diagnosis and, when available, the evaluation and monitoring of disease-modifying therapy.

摘要

神经退行性变的渐进性表明这是一个与年龄相关的过程,最终导致对记忆和高级心理功能至关重要的大脑皮质区域出现突触功能障碍和神经元损伤。发达国家人口老龄化加剧,这表明如果不加以控制,这些疾病将变得越来越普遍。在缺乏特异性生物标志物的情况下,对脑组织进行直接病理检查仍然是确诊阿尔茨海默病(AD)和其他类型痴呆的唯一确切方法。AD的病理特征是细胞内神经原纤维缠结(NFT)和细胞外淀粉样斑块。NFT是神经元内由成对螺旋丝组成的束,主要由异常磷酸化形式的tau蛋白聚集体构成;神经炎性斑块由β淀粉样蛋白(Aβ)的致密细胞外聚集体组成,周围伴有反应性胶质增生和营养不良性神经突。迄今为止,所有现有证据都有力地支持这样一种观点,即Aβ生成与清除之间的失衡导致其逐渐积累,这是AD发病机制的核心。对Aβ形成、降解和神经毒性分子机制的日益了解正在转化为新的治疗方法。虽然AD是老年人痴呆最常见的病因,但尸检研究发现路易体痴呆和额颞叶痴呆各占病例的20%左右。正电子发射断层扫描(PET)等分子神经成像技术已用于在分子作用部位进行体内分子过程评估,能够在无症状阶段检测出大脑细微的病理生理变化。用于非侵入性评估疾病特异性特征(如AD中的Aβ负荷)的分子成像方法的发展,使得在症状前阶段能够进行早期诊断、更准确的鉴别诊断,并且在可行时对疾病修饰治疗进行评估和监测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验